Baseline characteristics were balanced between the apixaban and warfarin cohorts. The mean age was 64 years with a mean CCI score of 2.7
| Warfarin cohort | Apixaban cohort | ||
|---|---|---|---|
| n (%) | n (%) | STD* | |
| Sample size | 25,602 | 17,493 | |
| Age, mean (SD) | 64.3 (14.3) | 64.5 (14.2) | 1.41 |
| Gender | |||
| Male | 10,504 (41.0) | 7,167 (41.0) | 0.12 |
| Female | 15,098 (59.0) | 10,326 (59.0) | 0.12 |
| Index VTE setting | |||
| Inpatient | 16,530 (64.6) | 11,321 (64.7) | 0.32 |
| Outpatient | 9,072 (35.4) | 6,172 (35.3) | 0.32 |
| Index VTE event type | |||
| DVT only | 12,214 (47.7) | 8,359 (47.8) | 0.16 |
| PE with or without DVT | 13,388 (52.3) | 9,134 (52.2) | 0.16 |
| Deyo-Charlson Comorbidity Index, Mean (SD) | 2.7 (2.6) | 2.7 (2.6) | 0.53 |
